CanSino Biologics Inc
SSE:688185

Watchlist Manager
CanSino Biologics Inc Logo
CanSino Biologics Inc
SSE:688185
Watchlist
Price: 60.21 CNY -1.67%
Market Cap: 6.9B CNY
Have any thoughts about
CanSino Biologics Inc?
Write Note

CanSino Biologics Inc
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CanSino Biologics Inc
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
CanSino Biologics Inc
SSE:688185
Total Liabilities & Equity
ÂĄ9.3B
CAGR 3-Years
11%
CAGR 5-Years
64%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Liabilities & Equity
ÂĄ33B
CAGR 3-Years
17%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Liabilities & Equity
ÂĄ17B
CAGR 3-Years
12%
CAGR 5-Years
15%
CAGR 10-Years
18%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Liabilities & Equity
ÂĄ48.2B
CAGR 3-Years
7%
CAGR 5-Years
13%
CAGR 10-Years
19%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Liabilities & Equity
ÂĄ54.4B
CAGR 3-Years
1%
CAGR 5-Years
2%
CAGR 10-Years
14%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Liabilities & Equity
ÂĄ1.4B
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

CanSino Biologics Inc
Glance View

Market Cap
6.9B CNY
Industry
Pharmaceuticals

CanSino Biologics Inc is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Tianjin, Tianjin and currently employs 1,946 full-time employees. The company went IPO on 2019-03-28. CanSino Biologics Inc is a clinical-stage vaccine company in China. The firm's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.

Intrinsic Value
100.07 CNY
Undervaluation 40%
Intrinsic Value
Price

See Also

What is CanSino Biologics Inc's Total Liabilities & Equity?
Total Liabilities & Equity
9.3B CNY

Based on the financial report for Dec 31, 2023, CanSino Biologics Inc's Total Liabilities & Equity amounts to 9.3B CNY.

What is CanSino Biologics Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
64%

Over the last year, the Total Liabilities & Equity growth was -19%. The average annual Total Liabilities & Equity growth rates for CanSino Biologics Inc have been 11% over the past three years , 64% over the past five years .

Back to Top